|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CBX5 |
Gene summary for CBX5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CBX5 | Gene ID | 23468 |
| Gene name | chromobox 5 | |
| Gene Alias | HEL25 | |
| Cytomap | 12q13.13 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P45973 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23468 | CBX5 | LZE2T | Human | Esophagus | ESCC | 2.36e-07 | 5.66e-01 | 0.082 |
| 23468 | CBX5 | LZE4T | Human | Esophagus | ESCC | 5.28e-05 | 1.46e-01 | 0.0811 |
| 23468 | CBX5 | LZE7T | Human | Esophagus | ESCC | 7.97e-07 | 5.74e-01 | 0.0667 |
| 23468 | CBX5 | LZE8T | Human | Esophagus | ESCC | 1.28e-05 | 1.90e-01 | 0.067 |
| 23468 | CBX5 | LZE20T | Human | Esophagus | ESCC | 1.26e-04 | 1.65e-01 | 0.0662 |
| 23468 | CBX5 | LZE22D1 | Human | Esophagus | HGIN | 1.60e-05 | 1.52e-01 | 0.0595 |
| 23468 | CBX5 | LZE22T | Human | Esophagus | ESCC | 5.49e-05 | 4.52e-01 | 0.068 |
| 23468 | CBX5 | LZE24T | Human | Esophagus | ESCC | 4.16e-07 | 1.19e-01 | 0.0596 |
| 23468 | CBX5 | LZE21T | Human | Esophagus | ESCC | 5.91e-03 | 3.43e-01 | 0.0655 |
| 23468 | CBX5 | LZE6T | Human | Esophagus | ESCC | 6.35e-13 | 3.52e-01 | 0.0845 |
| 23468 | CBX5 | P1T-E | Human | Esophagus | ESCC | 7.95e-17 | 6.51e-01 | 0.0875 |
| 23468 | CBX5 | P2T-E | Human | Esophagus | ESCC | 1.24e-77 | 1.62e+00 | 0.1177 |
| 23468 | CBX5 | P4T-E | Human | Esophagus | ESCC | 4.85e-22 | 5.91e-01 | 0.1323 |
| 23468 | CBX5 | P5T-E | Human | Esophagus | ESCC | 1.83e-26 | 6.41e-01 | 0.1327 |
| 23468 | CBX5 | P8T-E | Human | Esophagus | ESCC | 5.41e-30 | 8.00e-01 | 0.0889 |
| 23468 | CBX5 | P9T-E | Human | Esophagus | ESCC | 3.17e-23 | 3.38e-01 | 0.1131 |
| 23468 | CBX5 | P10T-E | Human | Esophagus | ESCC | 9.39e-26 | 5.87e-01 | 0.116 |
| 23468 | CBX5 | P11T-E | Human | Esophagus | ESCC | 4.10e-14 | 6.41e-01 | 0.1426 |
| 23468 | CBX5 | P12T-E | Human | Esophagus | ESCC | 2.63e-26 | 5.02e-01 | 0.1122 |
| 23468 | CBX5 | P15T-E | Human | Esophagus | ESCC | 1.78e-19 | 4.49e-01 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CBX5 | SNV | Missense_Mutation | novel | c.183N>C | p.Glu61Asp | p.E61D | P45973 | protein_coding | tolerated(0.9) | benign(0.173) | TCGA-AC-A5XS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | femara | SD |
| CBX5 | SNV | Missense_Mutation | novel | c.303N>G | p.Ile101Met | p.I101M | P45973 | protein_coding | tolerated(0.12) | benign(0.086) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| CBX5 | insertion | Nonsense_Mutation | novel | c.520_521insAGCAGTTATGTCTCCTGCATTCTTGGCTCCTGGATTTACC | p.Trp174Ter | p.W174* | P45973 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| CBX5 | insertion | Frame_Shift_Ins | novel | c.317dupA | p.Arg107GlufsTer6 | p.R107Efs*6 | P45973 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CBX5 | deletion | Frame_Shift_Del | novel | c.73delN | p.Val25CysfsTer2 | p.V25Cfs*2 | P45973 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| CBX5 | SNV | Missense_Mutation | novel | c.282N>A | p.Phe94Leu | p.F94L | P45973 | protein_coding | tolerated(0.34) | benign(0) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| CBX5 | SNV | Missense_Mutation | c.85C>T | p.Arg29Cys | p.R29C | P45973 | protein_coding | deleterious(0.05) | possibly_damaging(0.662) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |
| CBX5 | SNV | Missense_Mutation | novel | c.106N>A | p.Glu36Lys | p.E36K | P45973 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CBX5 | SNV | Missense_Mutation | c.143A>G | p.His48Arg | p.H48R | P45973 | protein_coding | deleterious(0) | possibly_damaging(0.484) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CBX5 | SNV | Missense_Mutation | c.555N>T | p.Glu185Asp | p.E185D | P45973 | protein_coding | tolerated(0.21) | benign(0.003) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |